PDGFRB and neoplasm: Additionally, sorafenib can target the platelet-derived growth factor receptor beta (PDGFR-β), the vascular endothelial growth factor receptor (VEGFR) 2, and the hepatocyte factor receptor (c-Met), among other proteins, to inhibit tumor angiogenesis [4].